The 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias incorporates significant new evidence from major randomized controlled trials, as well as relevant systematic reviews and meta-analyses published since 2019 and up until 31 March 2025. The Update targets specific areas in which new data on prognostics models, diagnostic accuracy studies and therapeutics, including assessment of risk-benefit ratios, could immediately influence clinical practice, providing revised or new recommendations.
Miteva et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: